282 related articles for article (PubMed ID: 28355112)
1. Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.
Zucca E; Conconi A; Martinelli G; Bouabdallah R; Tucci A; Vitolo U; Martelli M; Pettengell R; Salles G; Sebban C; Guillermo AL; Pinotti G; Devizzi L; Morschhauser F; Tilly H; Torri V; Hohaus S; Ferreri AJM; Zachée P; Bosly A; Haioun C; Stelitano C; Bellei M; Ponzoni M; Moreau A; Jack A; Campo E; Mazzucchelli L; Cavalli F; Johnson P; Thieblemont C
J Clin Oncol; 2017 Jun; 35(17):1905-1912. PubMed ID: 28355112
[TBL] [Abstract][Full Text] [Related]
2. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study.
Zucca E; Conconi A; Laszlo D; López-Guillermo A; Bouabdallah R; Coiffier B; Sebban C; Jardin F; Vitolo U; Morschhauser F; Pileri SA; Copie-Bergman C; Campo E; Jack A; Floriani I; Johnson P; Martelli M; Cavalli F; Martinelli G; Thieblemont C
J Clin Oncol; 2013 Feb; 31(5):565-72. PubMed ID: 23295789
[TBL] [Abstract][Full Text] [Related]
3. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.
Leblond V; Johnson S; Chevret S; Copplestone A; Rule S; Tournilhac O; Seymour JF; Patmore RD; Wright D; Morel P; Dilhuydy MS; Willoughby S; Dartigeas C; Malphettes M; Royer B; Ewings M; Pratt G; Lejeune J; Nguyen-Khac F; Choquet S; Owen RG
J Clin Oncol; 2013 Jan; 31(3):301-7. PubMed ID: 23233721
[TBL] [Abstract][Full Text] [Related]
4. Rituximab or rituximab plus chlorambucil for translocation (11;18)-negative gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomized observational study.
Lévy M; Dupuis J; Charpy C; Martin A; Itti E; Sobhani I; Haioun C; Amiot A
Leuk Lymphoma; 2022 Nov; 63(11):2597-2603. PubMed ID: 35687839
[TBL] [Abstract][Full Text] [Related]
5. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Ferreri AJ; Cwynarski K; Pulczynski E; Ponzoni M; Deckert M; Politi LS; Torri V; Fox CP; Rosée PL; Schorb E; Ambrosetti A; Roth A; Hemmaway C; Ferrari A; Linton KM; Rudà R; Binder M; Pukrop T; Balzarotti M; Fabbri A; Johnson P; Gørløv JS; Hess G; Panse J; Pisani F; Tucci A; Stilgenbauer S; Hertenstein B; Keller U; Krause SW; Levis A; Schmoll HJ; Cavalli F; Finke J; Reni M; Zucca E; Illerhaus G;
Lancet Haematol; 2016 May; 3(5):e217-27. PubMed ID: 27132696
[TBL] [Abstract][Full Text] [Related]
6. Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study.
Martinelli G; Montoro J; Vanazzi A; Andreola G; Liptrott S; Radice D; Negri M; Preda L; Pruneri G; Laszlo D
Hematol Oncol; 2015 Dec; 33(4):129-35. PubMed ID: 25047267
[TBL] [Abstract][Full Text] [Related]
7. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Samoilova O; Novak J; Ben-Yehuda D; Strugov V; Gill D; Gribben JG; Hsu E; Lih CJ; Zhou C; Clow F; James DF; Styles L; Flinn IW
Lancet Oncol; 2019 Jan; 20(1):43-56. PubMed ID: 30522969
[TBL] [Abstract][Full Text] [Related]
8. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial.
Hillmen P; Robak T; Janssens A; Babu KG; Kloczko J; Grosicki S; Doubek M; Panagiotidis P; Kimby E; Schuh A; Pettitt AR; Boyd T; Montillo M; Gupta IV; Wright O; Dixon I; Carey JL; Chang CN; Lisby S; McKeown A; Offner F;
Lancet; 2015 May; 385(9980):1873-83. PubMed ID: 25882396
[TBL] [Abstract][Full Text] [Related]
9. Rituximab, alkylating agents or combination therapy for gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomised observational study.
Amiot A; Lévy M; Copie-Bergman C; Dupuis J; Szablewski V; Le Baleur Y; Baia M; Belhadj K; Sobhani I; Leroy K; Haioun C; Delchier JC
Aliment Pharmacol Ther; 2014 Mar; 39(6):619-28. PubMed ID: 24467480
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
Iannitto E; Bellei M; Amorim S; Ferreri AJM; Marcheselli L; Cesaretti M; Haioun C; Mancuso S; Bouabdallah K; Gressin R; Tripodo C; Traverse-Glehen A; Baseggio L; Zupo S; Stelitano C; Castagnari B; Patti C; Alvarez I; Liberati AM; Merli M; Gini G; Cabras MG; Dupuis J; Tessoulin B; Perrot A; Re F; Palombi F; Gulino A; Zucca E; Federico M; Thieblemont C
Br J Haematol; 2018 Dec; 183(5):755-765. PubMed ID: 30407629
[TBL] [Abstract][Full Text] [Related]
11. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.
Herold M; Haas A; Srock S; Neser S; Al-Ali KH; Neubauer A; Dölken G; Naumann R; Knauf W; Freund M; Rohrberg R; Höffken K; Franke A; Ittel T; Kettner E; Haak U; Mey U; Klinkenstein C; Assmann M; von Grünhagen U;
J Clin Oncol; 2007 May; 25(15):1986-92. PubMed ID: 17420513
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
Salar A; Domingo-Domenech E; Estany C; Canales MA; Gallardo F; Servitje O; Fraile G; Montalbán C
Cancer; 2009 Nov; 115(22):5210-7. PubMed ID: 19672998
[TBL] [Abstract][Full Text] [Related]
13. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
Goede V; Fischer K; Busch R; Engelke A; Eichhorst B; Wendtner CM; Chagorova T; de la Serna J; Dilhuydy MS; Illmer T; Opat S; Owen CJ; Samoylova O; Kreuzer KA; Stilgenbauer S; Döhner H; Langerak AW; Ritgen M; Kneba M; Asikanius E; Humphrey K; Wenger M; Hallek M
N Engl J Med; 2014 Mar; 370(12):1101-10. PubMed ID: 24401022
[TBL] [Abstract][Full Text] [Related]
14. Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational study.
Lévy M; Copie-Bergman C; Amiot A; Dupuis J; Le Baleur Y; Belhadj K; Hémery F; Sobhani I; Delfau-Larue MH; Leroy K; Haioun C; Delchier JC
Leuk Lymphoma; 2013 May; 54(5):940-4. PubMed ID: 22978684
[TBL] [Abstract][Full Text] [Related]
15. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study.
Hillmen P; Gribben JG; Follows GA; Milligan D; Sayala HA; Moreton P; Oscier DG; Dearden CE; Kennedy DB; Pettitt AR; Nathwani A; Varghese A; Cohen D; Rawstron A; Oertel S; Pocock CF
J Clin Oncol; 2014 Apr; 32(12):1236-41. PubMed ID: 24638012
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study.
Oh SY; Kim WS; Kim JS; Kim SJ; Yoon DH; Yang DH; Lee WS; Kim HJ; Yhim HY; Jeong SH; Won JH; Lee S; Kong JH; Lim SN; Ji JH; Kwon KA; Lee GW; Lee JH; Lee HS; Shin HJ; Suh C
Cancer Commun (Lond); 2019 Oct; 39(1):58. PubMed ID: 31619290
[TBL] [Abstract][Full Text] [Related]
17. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.
Leonard JP; Trneny M; Izutsu K; Fowler NH; Hong X; Zhu J; Zhang H; Offner F; Scheliga A; Nowakowski GS; Pinto A; Re F; Fogliatto LM; Scheinberg P; Flinn IW; Moreira C; Cabeçadas J; Liu D; Kalambakas S; Fustier P; Wu C; Gribben JG;
J Clin Oncol; 2019 May; 37(14):1188-1199. PubMed ID: 30897038
[TBL] [Abstract][Full Text] [Related]
18. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
Matasar MJ; Capra M; Özcan M; Lv F; Li W; Yañez E; Sapunarova K; Lin T; Jin J; Jurczak W; Hamed A; Wang MC; Baker R; Bondarenko I; Zhang Q; Feng J; Geissler K; Lazaroiu M; Saydam G; Szomor Á; Bouabdallah K; Galiulin R; Uchida T; Soler LM; Cao A; Hiemeyer F; Mehra A; Childs BH; Shi Y; Zinzani PL
Lancet Oncol; 2021 May; 22(5):678-689. PubMed ID: 33848462
[TBL] [Abstract][Full Text] [Related]
19. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Sharman JP; Egyed M; Jurczak W; Skarbnik A; Pagel JM; Flinn IW; Kamdar M; Munir T; Walewska R; Corbett G; Fogliatto LM; Herishanu Y; Banerji V; Coutre S; Follows G; Walker P; Karlsson K; Ghia P; Janssens A; Cymbalista F; Woyach JA; Salles G; Wierda WG; Izumi R; Munugalavadla V; Patel P; Wang MH; Wong S; Byrd JC
Lancet; 2020 Apr; 395(10232):1278-1291. PubMed ID: 32305093
[TBL] [Abstract][Full Text] [Related]
20. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP).
Wöhrer S; Drach J; Hejna M; Scheithauer W; Dirisamer A; Püspök A; Chott A; Raderer M
Ann Oncol; 2003 Dec; 14(12):1758-61. PubMed ID: 14630681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
